Price to Earnings (P/E)
since 2005
Paying user area
Try for free
Vertex Pharmaceuticals Inc. pages available for free this week:
- Statement of Comprehensive Income
- Common-Size Income Statement
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Solvency Ratios
- Common Stock Valuation Ratios
- Selected Financial Data since 2005
- Net Profit Margin since 2005
- Operating Profit Margin since 2005
- Return on Assets (ROA) since 2005
- Debt to Equity since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Vertex Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Vertex Pharmaceuticals Inc., P/E, long-term trends, calculation
| P/E | = | Share price1, 2, 3 | ÷ | Earnings per share1 (EPS) | EPS1 | = | Net income (loss)1 (in thousands) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 13, 2026 | = | ÷ | = | ÷ | |||||||
| Feb 13, 2025 | = | ÷ | = | ÷ | |||||||
| Feb 15, 2024 | = | ÷ | = | ÷ | |||||||
| Feb 10, 2023 | = | ÷ | = | ÷ | |||||||
| Feb 9, 2022 | = | ÷ | = | ÷ | |||||||
| Feb 11, 2021 | = | ÷ | = | ÷ | |||||||
| Feb 13, 2020 | = | ÷ | = | ÷ | |||||||
| Feb 13, 2019 | = | ÷ | = | ÷ | |||||||
| Feb 15, 2018 | = | ÷ | = | ÷ | |||||||
| Feb 23, 2017 | = | ÷ | = | ÷ | |||||||
| Feb 16, 2016 | = | ÷ | = | ÷ | |||||||
| Feb 13, 2015 | = | ÷ | = | ÷ | |||||||
| Feb 11, 2014 | = | ÷ | = | ÷ | |||||||
| Mar 1, 2013 | = | ÷ | = | ÷ | |||||||
| Feb 22, 2012 | = | ÷ | = | ÷ | |||||||
| Feb 17, 2011 | = | ÷ | = | ÷ | |||||||
| Feb 19, 2010 | = | ÷ | = | ÷ | |||||||
| Feb 17, 2009 | = | ÷ | = | ÷ | |||||||
| Feb 11, 2008 | = | ÷ | = | ÷ | |||||||
| Mar 1, 2007 | = | ÷ | = | ÷ | |||||||
| Mar 16, 2006 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Vertex Pharmaceuticals Inc. Annual Report.
The price-to-earnings (P/E) ratio exhibits significant fluctuations over the observed period. Initially, the ratio is unavailable for several years, reflecting periods of negative earnings per share (EPS). A substantial P/E ratio of 267.42 is recorded in 2012, coinciding with a small positive EPS value following years of losses. Subsequently, the P/E ratio experiences considerable volatility, ranging from a high of 155.08 in 2017 to a low of 20.18 in 2021.
- Early Period (2006-2011)
- The P/E ratio is not calculable for the initial years due to consistently negative EPS. This indicates the company was not generating profits during this timeframe, making the P/E ratio meaningless as an investment metric.
- Transition and Volatility (2012-2017)
- The emergence of a positive, albeit small, EPS in 2012 results in a very high P/E ratio. This suggests the market had high expectations for future earnings growth. The P/E ratio then declines significantly to 155.08 in 2017, indicating increasing earnings and potentially a more rational market valuation. This period demonstrates considerable volatility, likely influenced by developments in the company’s pipeline and clinical trial results.
- Stabilization and Recent Trends (2018-2024)
- From 2018 onwards, the P/E ratio generally stabilizes, though fluctuations persist. The ratio decreases substantially in 2018 and 2019 as EPS increases dramatically. A subsequent rise in 2020 is followed by a decrease in 2021. In 2023, the P/E ratio is 30.42. The most recent available value, for 2024, shows a negative EPS and therefore an uncalculable P/E ratio.
Overall, the P/E ratio demonstrates a strong correlation with EPS. Periods of negative EPS result in an undefined P/E ratio, while increases in EPS generally lead to a decrease in the P/E ratio, and vice versa. The observed volatility suggests the market’s valuation of the company is sensitive to changes in earnings performance.
Comparison to Competitors
Vertex Pharmaceuticals Inc., P/E, long-term trends, comparison to competitors
| Vertex Pharmaceuticals Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 13, 2026 | ||||||||||||
| Feb 13, 2025 | ||||||||||||
| Feb 15, 2024 | ||||||||||||
| Feb 10, 2023 | ||||||||||||
| Feb 9, 2022 | ||||||||||||
| Feb 11, 2021 | ||||||||||||
| Feb 13, 2020 | ||||||||||||
| Feb 13, 2019 | ||||||||||||
| Feb 15, 2018 | ||||||||||||
| Feb 23, 2017 | ||||||||||||
| Feb 16, 2016 | ||||||||||||
| Feb 13, 2015 | ||||||||||||
| Feb 11, 2014 | ||||||||||||
| Mar 1, 2013 | ||||||||||||
| Feb 22, 2012 | ||||||||||||
| Feb 17, 2011 | ||||||||||||
| Feb 19, 2010 | ||||||||||||
| Feb 17, 2009 | ||||||||||||
| Feb 11, 2008 | ||||||||||||
| Mar 1, 2007 | ||||||||||||
| Mar 16, 2006 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Vertex Pharmaceuticals Inc., P/E, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Vertex Pharmaceuticals Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 13, 2026 | ||
| Feb 13, 2025 | ||
| Feb 15, 2024 | ||
| Feb 10, 2023 | ||
| Feb 9, 2022 | ||
| Feb 11, 2021 | ||
| Feb 13, 2020 | ||
| Feb 13, 2019 | ||
| Feb 15, 2018 | ||
| Feb 23, 2017 | ||
| Feb 16, 2016 | ||
| Feb 13, 2015 | ||
| Feb 11, 2014 | ||
| Mar 1, 2013 | ||
| Feb 22, 2012 | ||
| Feb 17, 2011 | ||
| Feb 19, 2010 | ||
| Feb 17, 2009 | ||
| Feb 11, 2008 | ||
| Mar 1, 2007 | ||
| Mar 16, 2006 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Vertex Pharmaceuticals Inc., P/E, long-term trends, comparison to industry (health care)
| Vertex Pharmaceuticals Inc. | Health Care | |
|---|---|---|
| Feb 13, 2026 | ||
| Feb 13, 2025 | ||
| Feb 15, 2024 | ||
| Feb 10, 2023 | ||
| Feb 9, 2022 | ||
| Feb 11, 2021 | ||
| Feb 13, 2020 | ||
| Feb 13, 2019 | ||
| Feb 15, 2018 | ||
| Feb 23, 2017 | ||
| Feb 16, 2016 | ||
| Feb 13, 2015 | ||
| Feb 11, 2014 | ||
| Mar 1, 2013 | ||
| Feb 22, 2012 | ||
| Feb 17, 2011 | ||
| Feb 19, 2010 | ||
| Feb 17, 2009 | ||
| Feb 11, 2008 | ||
| Mar 1, 2007 | ||
| Mar 16, 2006 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).